<DOC>
	<DOCNO>NCT01484964</DOCNO>
	<brief_summary>The purpose study determine bioavailability pharmacokinetics two different formulation ASP015K tablet determine food effect absorption new formulation .</brief_summary>
	<brief_title>A Single Oral Dose Study Compare Bioavailability Between Two Different Tablet Formulations Assess There Food Effect With New Formulation</brief_title>
	<detailed_description>Eligible subject admit Day -2 remain confined unit 20 day . Each subject receive single dose study drug per define treatment period morning Day 1 , Day 8 Day 15 . There minimum 7 day consecutive dose group . For Treatment A , Formulation 1 tablet administer within 30 minute start standard FDA moderate-fat breakfast . Treatment B , Formulation 2 tablet administer fasted state . For Treatment C , Formulation 2 tablet administer within 30 minute start standard FDA moderate-fat breakfast . Any subject discontinuing study prior completion end study evaluation complete</detailed_description>
	<criteria>Subject weigh least 45 kg body mass index ( BMI ) 1832 kg/m2 Male subject agree sexual abstinence , surgically sterile use medically acceptable method prevent pregnancy agree continue use method 90 day last dose study drug administration Male subject agrees donate sperm 90 day dose study drug administration Female subject surgically sterile postmenopausal pregnant lactating Subject 's 12lead electrocardiogram ( ECG ) normal Subject must capable swallow multiple tablet Subject willing take complete moderatefat breakfast within 30 minute Subject previous history clinically significant gastrointestinal , neurological , renal , hepatic , pulmonary , metabolic , cardiovascular , psychiatric , endocrine , hematological disorder disease , malignancy exclude nonmelanoma skin cancer medical condition Subject major GI surgery ( colectomy , cholecystectomy , etc ) Subject history consume 14 unit alcoholic beverage per week history alcoholism drug/chemical/ substance abuse within past 2 year Subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week Subject positive test hepatitis C antibody , positive test hepatitis B surface antigen ( HBsAg ) , positive hepatitis B core antibody Subject history human immunodeficiency virus ( HIV ) antibody Subject positive tuberculosis ( TB ) skin test , Quantiferon Gold test TSPOTÂ® test Subject receive vaccine within 60 day Subject receive experimental agent within 30 day Subject absolute neutrophil count ( ANC ) &lt; 2500 cells/mm3 Subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day Subject history smoking use tobaccocontaining product nicotine nicotinecontaining product past six month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>healthy subject</keyword>
	<keyword>bioavailability</keyword>
	<keyword>food effect</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>transplantation</keyword>
</DOC>